Omega Therapeutics, Inc. Contracts & Agreements
63 Contracts & Agreements
- Business Finance (10 contracts)
- Business Operations (5)
- Human Resources (20)
- Intellectual Property (5)
- Real Estate (5)
- Uncategorized (18)
- Shared Space Arrangement by and between Omega Therapeutics, Inc. and Flagship Labs 104, Inc., effective September 1, 2024 (Filed With SEC on August 30, 2024)
- Shared Space Arrangement by and between Omega Therapeutics, Inc. and Flagship Labs 101, Inc., effective September 1, 2024 (Filed With SEC on August 30, 2024)
- Amended and Restated Shared Space Arrangement by and between Omega Therapeutics, Inc. and Prologue Medicines, Inc. (formerly Flagship Labs 89, Inc.), effective September 1, 2024 (Filed With SEC on August 30, 2024)
- Amended and Restated Shared Space Arrangement by and between Omega Therapeutics, Inc. and Metaphore Biotechnologies, Inc., effective September 1, 2024 (Filed With SEC on August 30, 2024)
- Amended and Restated Shared Space Arrangement by and between Omega Therapeutics, Inc. and Apriori Bio, Inc., effective September 1, 2024 (Filed With SEC on August 30, 2024)
- Third Amendment to Lease Agreement, dated July 31, 2024 between Omega Therapeutics, Inc. and ARE-MA Region No. 94, LLC (Filed With SEC on August 6, 2024)
- Second Amendment to Lease Agreement, dated June 24, 2024 between Omega Therapeutics, Inc. and ARE-MA Region No. 94, LLC (Filed With SEC on August 6, 2024)
- Shared Space Agreement, dated August 1, 2024 by and between Omega Therapeutics, Inc. and Flagship Labs 97, Inc (Filed With SEC on August 6, 2024)
- Amendment, dated June 17, 2024 to Shared Space Agreement, dated July 12, 2023, by and between Omega Therapeutics, Inc. and Flagship Labs 89, Inc. (now known as Prologue Medicines,... (Filed With SEC on August 6, 2024)
- Amendment, dated June 17, 2024 to Shared Space Agreement, dated July 11, 2023, by and between Omega Therapeutics, Inc. and Apriori Bio, Inc (Filed With SEC on August 6, 2024)
- Amendment, dated June 17, 2024 to Shared Space Agreement, dated July 12, 2023, by and between Omega Therapeutics, Inc. and Metaphore Biotechnologies, Inc (Filed With SEC on August 6, 2024)
- Amended and Restated Employment Agreement, by and between Omega Therapeutics, Inc. and Barbara Chan, dated May 28, 2024 (Filed With SEC on August 6, 2024)
- Separation Agreement, by and between Omega Therapeutics, Inc. and Joshua Reed, dated June 3, 2024 (Filed With SEC on August 6, 2024)
- Separation Agreement, by and between Omega Therapeutics, Inc. and Yan Moore, M.D., dated June 5, 2024 (Filed With SEC on August 6, 2024)
- Non-Employee Director Compensation Program, effective May 28, 2024 (Filed With SEC on August 6, 2024)
- Omega Therapeutics, Inc. 2021 Incentive Award Plan Stock Option Grant Notice and Stock Option Agreement issued to Mahesh Karande on February 7, 2024 (Filed With SEC on May 6, 2024)
- Waiver, Confirmation and Agreement Regarding Research Collaboration effective December 31, 2023, between Whitehead Institute for Biomedical Research and the Registrant, relating... (Filed With SEC on March 28, 2024)
- Waiver, Confirmation and Agreement Regarding Research Collaboration effective December 31, 2023, between Whitehead Institute for Biomedical Research and the Registrant, relating... (Filed With SEC on March 28, 2024)
- Letter Agreement re License Agreement between Flagship Pioneering Innovations V, Inc. and the Registrant dated December 31, 2023 relating to the License Agreement dated March 12,... (Filed With SEC on March 28, 2024)
- Amendment to Consulting Agreement by and between Richard A. Young and the Registrant, dated October 6, 2023 (Filed With SEC on March 28, 2024)
- Amendment to Consulting Agreement by and between Richard A. Young and the Registrant, dated October 5, 2022 (Filed With SEC on March 28, 2024)
- Employment Agreement by and between Joshua Reed and the Registrant, dated April 28, 2022 (Filed With SEC on March 28, 2024)
- Fifth Amendment to Loan and Security Agreement, dated September 22, 2023 (Filed With SEC on September 22, 2023)
- Open Market Sale Agreement, dated as of August 3, 2023, between Omega Therapeutics, Inc. and Jefferies LLC (Filed With SEC on August 3, 2023)
- First Amendment to Lease between Omega Therapeutics, Inc. and ARE-MA Region No. 94, LLC, dated May 3, 2023 (Filed With SEC on August 3, 2023)
- Shared Space Arrangement, dated as of July 12, 2023, by and between Omega Therapeutics, Inc. and Flagship Labs 89, Inc (Filed With SEC on July 13, 2023)
- Shared Space Arrangement, dated as of July 11, 2023, by and between Omega Therapeutics, Inc. and Apriori Bio, Inc (Filed With SEC on July 13, 2023)
- Shared Space Arrangement, dated as of July 12, 2023, by and between Omega Therapeutics, Inc. and Metaphore Biotechnologies, Inc (Filed With SEC on July 13, 2023)
- Form of Securities Purchase Agreement (Filed With SEC on February 23, 2023)
- Employment Agreement by and between Kevin McManus and the Registrant, dated February 3, 2022 (Filed With SEC on May 4, 2022)
- Employment Agreement by and between Joshua Reed and the Registrant, dated April 28, 2022 (Filed With SEC on May 4, 2022)
- Employment Agreement by and between Ling Zeng and the Registrant, dated March 18, 2022 (Filed With SEC on May 4, 2022)
- Amendment to Shared Space Agreement between Omega Therapeutics, Inc. and Senda Biosciences, Inc., dated January 31, 2022 (Filed With SEC on March 10, 2022)
- Lease Agreement between Omega Therapeutics, Inc. and ARE-MA Region No, 94, LLC (Filed With SEC on March 10, 2022)
- Amendment to Consulting Agreement by and between Richard A. Young and the Registrant, dated October 29, 2021 (Filed With SEC on March 10, 2022)
- Consulting Agreement by and between Richard A. Young and the Registrant, dated November 7, 2016 (Filed With SEC on March 10, 2022)
- Employment Agreement by and between Yan Moore and the Registrant, dated December 12, 2021 (Filed With SEC on March 10, 2022)
- Description of Capital Stock (Filed With SEC on March 10, 2022)
- Fourth Amendment to Loan and Security Agreement, dated December 20, 2021 (Filed With SEC on December 21, 2021)
- Form of Indemnification Agreement for Directors and Officers (Filed With SEC on July 26, 2021)
- Form of Underwriting Agreement (Filed With SEC on July 26, 2021)
- Specimen Stock Certificate evidencing the shares of common stock (Filed With SEC on July 26, 2021)
- 2021 Incentive Award Plan and form of agreements thereunder (Filed With SEC on July 26, 2021)
- 2021 Employee Stock Purchase Plan (Filed With SEC on July 26, 2021)
- Non-Employee Director Compensation Program (Filed With SEC on July 26, 2021)
- Shared Space Arrangement between Kintai Therapeutics, Inc. (n/k/a Senda Biosciences, Inc.) and the Registrant, dated July 13, 2020 (Filed With SEC on July 26, 2021)
- Loan and Security Agreement between Pacific Western Bank (n/k/a PacWest Bancorp) and the Registrant, dated March 9, 2018, as amended on September 30, 2019, January 22, 2020 and... (Filed With SEC on July 26, 2021)
- Development and Option Agreement between Acuitas Therapeutics, Inc. and the Registrant, dated October 5, 2020, as amended (Filed With SEC on July 26, 2021)
- Employment Agreement between Mahesh Karande and the Registrant, dated July 25, 2021 (Filed With SEC on July 26, 2021)
- Employment Agreement between Thomas McCauley and the Registrant, dated July 24, 2021 (Filed With SEC on July 26, 2021)
- Employment Agreement between Roger Sawhney and the Registrant, dated July 24, 2021 (Filed With SEC on July 26, 2021)
- Lease Agreement between BMR-325 Vassar Street LLC and the Registrant, dated November 30, 2017 (Filed With SEC on July 26, 2021)
- Development and Option Agreement between Acuitas Therapeutics, Inc. and the Registrant, dated October 5, 2020, as amended (Filed With SEC on July 9, 2021)
- Amended and Restated Warrant to Purchase Stock issued to PacWest Bancorp, dated September 30, 2019, to purchase Series A preferred stock (Filed With SEC on July 9, 2021)
- 2017 Equity Incentive Plan, as amended, and form of option agreements thereunder (Filed With SEC on July 9, 2021)
- Offer Letter between Mahesh Karande and the Registrant, dated March 2, 2019 (Filed With SEC on July 9, 2021)
- Offer Letter between Tom McCauley and the Registrant, dated July 10, 2019 (Filed With SEC on July 9, 2021)
- Offer Letter between Roger Sawhney and the Registrant, dated March 25, 2020 (Filed With SEC on July 9, 2021)
- License Agreement between Flagship Pioneering Innovations V, Inc. and the Registrant, dated March 12, 2019 (Filed With SEC on July 9, 2021)
- Exclusive License Agreement between the Whitehead Institute for Biomedical Research and the Registrant, dated May 22, 2019 (Filed With SEC on July 9, 2021)
- Co-Exclusive License Agreement between the Whitehead Institute for Biomedical Research and the Registrant, dated May 22, 2019 (Filed With SEC on July 9, 2021)
- Non-Exclusive License Agreement between Acuitas Therapeutics, Inc. and the Registrant, dated March 22, 2021 (Filed With SEC on July 9, 2021)
- Amended and Restated Investors Rights Agreement, dated March 4, 2021 (Filed With SEC on July 9, 2021)
